Tech Optimist Episode 29: Three Breakthroughs — Exciting News on Alzheimer’s, Warming Globe Problems and Solutions, and Smart Antibiotics
Alumni Ventures CEO Mike Collins and Managing Partner Matt Caspari discuss three groundbreaking advancements
Tech Optimist, presented by Alumni Ventures, focuses on the intersection of technology, entrepreneurship, and innovation. We are passionate about technology and its potential to drive positive change. We explore our lane through with founders, investors, and futurists; discussions of new innovations; and reviews of trends in technology and venture capital. Subscribe Here »
In our latest Three Breakthroughs segment, Alumni Ventures Founder and CEO Mike Collins and Managing Partner Matt Caspari explore three breakthroughs that could redefine our health and environment:
- The promising FDA approval of a new Alzheimer’s drug, offering hope in slowing the progression of this debilitating disease.
- The pressing issue of global warming, discussing the record-breaking heat of summer 2023 and innovative solutions aimed at combating climate change.
- The revolutionary new smart antibiotic, which promises efficacy without compromising the microbiome, potentially transforming medical treatments.
Join Mike and Matt as they delve into these technological advancements that hold the potential to dramatically improve our world.
Listen Here »
Alumni Ventures offers accredited individuals access to professional-grade venture capital, a key asset class missing from the portfolios of many sophisticated investors. Since 2014, AV has raised $1.3+ billion from 10,000+ investors and backed 1,300+ unique portfolio companies. AV is a top 20 venture firm in North America according to CB Insights, as well as the #1 most active venture firm in the U.S., and #3 most active in the world, according to PitchBook’s 2022 and 2023 rankings. AV has won awards from Inc. Magazine, Fast Company, Benzinga, and the US FinTech Awards.
